Brain Imaging: Cocaine Effects & Medication Development - 5 - Full Text View

Brain Imaging: Cocaine Effects & Medication Development - 5

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) New York State Psychiatric Institute
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000270

Purpose

The purpose of this study is to define temporal profile of brain activation (rCBF) using Xenon-SPECT and O 15-PET.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Cocaine	Phase IV

Drug Information available for:

8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Brain Imaging: Cocaine Effects & Medication Development

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Absolute change in rCBF at 5 & 15 minutes (Xe)
Relative change in rCBF at 5, 19, & 33 minutes (O15)
Correlated with a) subjective effects, b) venous blood level of coca, c) autonomic variables

Estimated Enrollment:	0
Study Start Date:	May 1995

Eligibility

Ages Eligible for Study:	18 Years to 48 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000270

Locations


United States, New York
	New York State Psychiatric Institute
	New York, New York, United States, 10032

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

New York State Psychiatric Institute

Investigators


Principal Investigator:	Herbert Kleber, M.D.	New York State Psychiatric Institute

More Information

Publications:

ACNP Abstract, 1995. CPDD Abstract, 1996. Society for Nuclear Medicine, 1996. Society for Neuroscience, 1997.

Study ID Numbers:	NIDA-09236-5, P50-09236-5
First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000270
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Cocaine-Related Disorders

Dopamine

Mental Disorders

Substance-Related Disorders

Disorders of Environmental Origin

Cocaine

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors

Neurotransmitter Agents

Neurotransmitter Uptake Inhibitors

Molecular Mechanisms of Pharmacological Action

Physiological Effects of Drugs

Anesthetics

Central Nervous System Depressants

Cardiovascular Agents

Pharmacologic Actions

Anesthetics, Local

Sensory System Agents

Therapeutic Uses

Vasoconstrictor Agents

Dopamine Agents

Peripheral Nervous System Agents

Central Nervous System Agents

ClinicalTrials.gov processed this record on December 03, 2008